Novel Gene Therapy Based on Modified Version of CRISPR/Cas9 Tool
|
By LabMedica International staff writers Posted on 21 Dec 2017 |

Image: An advanced in vivo Cas9-based epigenetic gene activation system enhances skeletal muscle mass (top) and fiber size growth (bottom) in a treated mouse (right) compared with an independent control (left). The fluorescent microscopy images at bottom show purple staining of the laminin glycoprotein in tibialis anterior muscle fibers (Photo courtesy of the Salk Institute for Biological Research).
A modified form of the CRISPR/Cas9 gene-editing tool does not cause "double-strand breaks" (DSBs) in the DNA, yet it retains the ability to target and activate specific sites in the genome.
CRISPR/Cas9 is regarded as the cutting edge of molecular biology technology. CRISPRs (clustered regularly interspaced short palindromic repeats) are segments of prokaryotic DNA containing short repetitions of base sequences. Each repetition is followed by short segments of "spacer DNA" from previous exposures to a bacterial virus or plasmid. CRISPRs are found in approximately 40% of sequenced bacteria genomes and 90% of sequenced archaea. CRISPRs are often associated with cas genes that code for proteins related to CRISPRs.
Since 2013, the CRISPR/Cas system has been used in research for gene editing (adding, disrupting, or changing the sequence of specific genes) and gene regulation. By delivering the Cas9 enzyme and appropriate guide RNAs (gRNAs) into a cell, the organism's genome can be cut at any desired location. The conventional CRISPR/Cas9 system is composed of two parts: the Cas9 enzyme, which cleaves the DNA molecule and specific RNA guides that shepherd the Cas9 protein to the target gene on a DNA strand.
In a paper published in the December 7, 2017, online edition of the journal Cell, investigators at the Salk Institute for Biological Research (La Jolla, CA, USA) used a modified version of CRISPR/Cas9. This version is based on a catalytically inactive form of Cas9 (dCas9), which can still target specific sites in the genome, but no longer induces DSBs that cut DNA. CRISPR/dCas9 associates with transcriptional activation domains, which are molecular switches that activate targeted genes.
Delivery of the CRISPR/dCas9 complex required development of a new methodology, as it was too large to fit into the commonly used adeno-associated virus (AAV) transport system. Therefore, the investigators separated the editing tool into its two primary components by generating a dual-AAV system based on co-injection of AAV-dCas9 with a separate AAV-gRNA.
The investigators used this technique to treat mouse models of diabetes, muscular dystrophy, and acute kidney disease. Results demonstrated that CRISPR/dCas9-mediated target gene activation could be achieved in vivo, leading to measurable phenotypes and amelioration of disease symptoms.
"Although many studies have demonstrated that CRISPR/Cas9 can be applied as a powerful tool for gene therapy, there are growing concerns regarding unwanted mutations generated by the double-strand breaks through this technology," said senior author Dr. Juan Carlos Izpisua Belmonte, a professor in the gene expression laboratory at the Salk Institute for Biological Research. "We were able to get around that concern."
Related Links:
Salk Institute for Biological Research
CRISPR/Cas9 is regarded as the cutting edge of molecular biology technology. CRISPRs (clustered regularly interspaced short palindromic repeats) are segments of prokaryotic DNA containing short repetitions of base sequences. Each repetition is followed by short segments of "spacer DNA" from previous exposures to a bacterial virus or plasmid. CRISPRs are found in approximately 40% of sequenced bacteria genomes and 90% of sequenced archaea. CRISPRs are often associated with cas genes that code for proteins related to CRISPRs.
Since 2013, the CRISPR/Cas system has been used in research for gene editing (adding, disrupting, or changing the sequence of specific genes) and gene regulation. By delivering the Cas9 enzyme and appropriate guide RNAs (gRNAs) into a cell, the organism's genome can be cut at any desired location. The conventional CRISPR/Cas9 system is composed of two parts: the Cas9 enzyme, which cleaves the DNA molecule and specific RNA guides that shepherd the Cas9 protein to the target gene on a DNA strand.
In a paper published in the December 7, 2017, online edition of the journal Cell, investigators at the Salk Institute for Biological Research (La Jolla, CA, USA) used a modified version of CRISPR/Cas9. This version is based on a catalytically inactive form of Cas9 (dCas9), which can still target specific sites in the genome, but no longer induces DSBs that cut DNA. CRISPR/dCas9 associates with transcriptional activation domains, which are molecular switches that activate targeted genes.
Delivery of the CRISPR/dCas9 complex required development of a new methodology, as it was too large to fit into the commonly used adeno-associated virus (AAV) transport system. Therefore, the investigators separated the editing tool into its two primary components by generating a dual-AAV system based on co-injection of AAV-dCas9 with a separate AAV-gRNA.
The investigators used this technique to treat mouse models of diabetes, muscular dystrophy, and acute kidney disease. Results demonstrated that CRISPR/dCas9-mediated target gene activation could be achieved in vivo, leading to measurable phenotypes and amelioration of disease symptoms.
"Although many studies have demonstrated that CRISPR/Cas9 can be applied as a powerful tool for gene therapy, there are growing concerns regarding unwanted mutations generated by the double-strand breaks through this technology," said senior author Dr. Juan Carlos Izpisua Belmonte, a professor in the gene expression laboratory at the Salk Institute for Biological Research. "We were able to get around that concern."
Related Links:
Salk Institute for Biological Research
Latest BioResearch News
- BRCA2 Variant Analysis Offers Insights Into Breast Cancer Risk and Treatment
- Statistical Model Helps Track T Cell Behavior During Cancer Immunotherapy
- Blood NAD Levels May Offer Clues to Cardiovascular Health
- Organ-on-Chip System Offers Insights Into Tumor Interactions and Treatment Response
- Multiplexed Single-Cell DNA Methylation Workflow Enables Analysis of Blood Disorders
- Extracellular Vesicle Biomarkers Reveal Shared Signals in Aging and Cancer
- Study Reveals Regulatory DNA Element Involved in Breast Cancer Growth Suppression
- New ddPCR Assays Broaden Options for Multiplex Cancer Mutation Research
- Platelet Biomarkers Identify Progression Signals in Parkinson's Disease
- Molecular Atlas Offers New Framework for Breast Cancer Risk and Treatment Research
- New Method Isolates Neuron-Linked Vesicles From Blood and Cerebrospinal Fluid
- Lung Tumor RNA Variants Offer Clues to Immunotherapy Benefit
- Population-Scale Genome Survey Supports Interpretation of Genetic Testing
- Single-Cell Profiling Reveals Chemotherapy Resistance Signals in Ovarian Cancer
- Genomic Tool Supports Analysis of Repeat Expansions Linked to Inherited Disorders
- CSF Biomarker Meprin-Beta Increases in Alzheimer’s Disease
Channels
Clinical Chemistry
view channelAI and Nanotechnology Enable Five-Minute Urine Drug Screening
Rapid screening for illicit drugs remains challenging when testing must be performed at the point of care. Laboratory methods provide accurate results but require sample preparation and specialized equipment,... Read more
Study Questions Uniform Stool-Test Cutoff Across Age Groups
Colorectal cancer remains a major clinical challenge, ranking as the fourth most common cancer and the second-leading cause of cancer death in the U.K. Early-onset colorectal cancer, defined as diagnosis... Read moreMolecular Diagnostics
view channel
Blood RNA Patterns Linked to CAR T-Cell Response and Survival in Lymphoma
Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, which involves engineering a patient’s own immune cells to recognize and attack cancer cells, has transformed treatment for large B-cell lymphoma,... Read moreGenome Sequencing Provides Clues to Unexplained Recurrent Miscarriages
Recurrent pregnancy loss, defined as two or more miscarriages, affects about 5% of couples. In many cases, routine evaluation does not identify a cause, particularly when pregnancies have a normal chromosome... Read moreHematology
view channel
Werfen Gains FDA Clearance for ROTEM sigma Cartridge Use in Trauma
Traumatic injuries account for approximately 10% of deaths worldwide, with uncontrolled bleeding remaining a leading cause of potentially preventable trauma-related death. Trauma-induced coagulopathy further... Read more
Serial Blood Samples Reveal Leukemia’s Evolution Decades Before Diagnosis
Acute myeloid leukemia (AML) is an aggressive blood cancer affecting approximately 2,700 people in the U.K. annually, with only about one in six patients surviving five years after diagnosis.... Read moreImmunology
view channel
Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice
Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more
Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis
Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more
Antibody Testing Informs Melioidosis Diagnosis and Surveillance in Emerging Regions
Melioidosis is a serious and sometimes fatal infection caused by the soil- and water-dwelling bacterium Burkholderia pseudomallei. People and animals can contract the disease through exposure to contaminated... Read moreMicrobiology
view channel
WHO Survey Reveals Gaps in Antimicrobial Resistance Testing and Response
Antimicrobial resistance (AMR) remains a major challenge for health systems, limiting effective treatment options for drug-resistant infections. These infections caused more than 1 million deaths and contributed... Read more
Direct-From-Specimen Pneumonia Test Detects Pathogens and Resistance in Hours
Pneumonia is a leading cause of sepsis and is associated with high mortality. Conventional culture-based pathogen identification and antimicrobial susceptibility testing can take two to four days, delaying... Read morePathology
view channel
Researchers Evaluate Automated Tissue Analysis Across Four Cancer Types
Histopathology image analysis plays a central role in cancer diagnosis, but tumor tissue can vary considerably across different regions of the same specimen. Pathologists examine cellular morphology, nuclear... Read more
AI Prostate Cancer Test Added to NCCN Guidelines for Post-Surgery Recurrence
Following radical prostatectomy, an estimated 20% to 40% of prostate cancer patients develop biochemical recurrence, marked by rising prostate-specific antigen levels that may indicate cancer recurrence.... Read more
New Training Approach Helps AI Distinguish Neighboring Cells in Tissue
Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more
Review Highlights Progress and Validation Needs for AI in Digital Pathology
Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read moreTechnology
view channel
Experimental Blood Test Detects Markers of Three Cancers and Alzheimer’s Disease
Colorectal cancer, glioblastoma, pancreatic cancer, and Alzheimer’s disease are serious conditions in which earlier detection may improve clinical outcomes. Blood-based testing could help identify dis... Read more
New qPCR Master Mixes Offer Broad Compatibility for Routine Research
Quantitative PCR (qPCR) workflows require consistent reagent performance across instruments and assay formats. Laboratories must also manage costs without changing established protocols.... Read moreIndustry
view channel
Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil
Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more







